Skip to main content

Cancer: Cervical

Volume 685: debated on Monday 9 October 2006

asked Her Majesty's Government:

What assessment they are undertaking of the availability of vaccines against the causes of cervical cancer; which body is conducting such work; and to what timeframe.[HL7070]

We are aware of the two vaccines in development by GlaxoSmithKline and Merck Sharp & Dhome.

The Department of Health has worked closely with the Health Protection Agency, the National Institute for Biological Standards and Control, the National Institute for Health and Clinical Excellence, NHS Cancer Screening Programmes and prominent researchers in the field to inform a potential strategy for the NHS when the vaccines become available.

The Joint Committee on Vaccination and Immunisation (JCVI) has now set up a sub-group to consider human papilloma virus vaccination. The sub-group met firstly on 23 May 2006, and manufacturers were invited to submit material for the group to consider. The sub-group will next meet on 22 September, prior to preparing a report to go to the main JCVI meeting in October.